View Article

Abstract

Traditional medicine and modern allopathic medicine represent two of the world’s most influential health systems. Herbal medicine, rooted in cultural traditions such as Ayurveda and ethnomedicine, has seen increasing global use due to its holistic perspectives and perceived safety. Meanwhile, allopathic (biomedical) medicine remains the dominant scientific paradigm, characterized by reductionism, evidence-based diagnostics, and targeted pharmacology. This review compares the philosophical foundations, therapeutic principles, safety, efficacy, and modern integration of traditional herbal systems with allopathic medicine. It also highlights advancements such as network pharmacology, systems biology, reverse pharmacology, AI-assisted herbal research, and regulatory frameworks. By analyzing 80 academic sources, this paper outlines how traditional knowledge and modern science can converge to build integrated healthcare models that are safer, more effective, and culturally relevant.

Keywords

Herbal medicine, Allopathic medicine, Integrative medicine, Ayurveda Systems biology, Network pharmacology, Reverse pharmacology, Polyherbal formulations, Phytochemicals, Herb–drug interactions, Quality control and standardization

Introduction

Traditional medical systems have guided human health for millennia. Texts such as the Charaka Samhita reflect highly systematized medical knowledge in India (1), while works like Medicine in China describe the philosophical roots of TCM (2). In contrast, modern allopathic medicine emerged through anatomical discoveries, scientific experimentation, and pharmacological advances documented by historians such as Porter (3,42). Both systems have coexisted and influenced each other, yet their relationship remains complex and sometimes polarized.

Globally, the burden of chronic diseases such as cardiovascular disease, diabetes, cancer, and inflammatory disorders continues to intensify (4,28,29). This epidemiological shift has prompted renewed interest in holistic and preventive healing systems, including Ayurveda which emphasize balance, constitution-based therapy, and lifestyle interventions (5,7,9,40). Meanwhile, modern medicine relies on standardized diagnostics, randomized control trials, and molecular pharmacology to provide rapid and effective treatment (8,48). According to WHO, over 80% of the world’s population uses some form of traditional herbal medicine (5). In India, AYUSH systems have witnessed rapid institutional expansion (13), while in China, integrative hospitals employing both TCM and Western medicine have become standard (12,23). However, concerns remain regarding standardization, toxicological risks, variability in herbal composition, and lack of reproducible evidence (6,20,36,51).

This review aims to critically evaluate:

  1. Philosophical foundations of herbal vs allopathic medicine
  2. Safety and efficacy of herbal medicines
  3. Molecular mechanisms: phytochemicals, polyherbal synergy, network pharmacology
  4. Advances such as reverse pharmacology, AI-driven discovery, nanocarriers
  5. Regulatory and quality control challenges
  6. Pathways for meaningful integration

2. Philosophical Foundations of Herbal and Allopathic Medicine

2.1 Ayurveda: Holism, Doshas, and Systems Thinking

Ayurveda emphasizes balance among doshas (Vata, Pitta, Kapha), digestive fire (agni), and tissue formation (dhatus) (1,45). Its epistemology is rooted in observation, inference, and experiential validation (49). Ayurveda views disease as systemic imbalance rather than isolated pathology, aligning with modern systems biology (9). Zimmermann’s work emphasizes the holistic worldview underlying Ayurvedic formulations and personalized therapy (40).

2.2 Allopathic Medicine: Reductionism and Evidence-Based Practice

Allopathic medicine evolved through scientific rationalism, anatomical research, and technological advances. Sackett’s definition of evidence-based medicine (EBM) emphasizes clinical data, patient values, and scientific judgment (8). Ioannidis critiques reproducibility issues but supports rigorous methodology as the backbone of modern therapeutics (51).

2.3 Convergence Through Systems Biology and Network Science

Systems biology, integrative omics, and network pharmacology provide frameworks to understand multi-target herbal actions (10,11,24,43). These approaches reconcile traditional multi-component formulations with molecular pharmacology, bridging holistic and reductionist paradigms

3. Safety Concerns and Quality Control of Herbal Medicines

3.1 Growing Use and Associated Risks

Herbal medicine popularity has surged worldwide (6,80), yet concerns include:

  • Adulteration with synthetic drugs
  • Heavy metal contamination
  • Microbiological growth
  • Variability in phytochemical potency
  • Herb–drug interactions (20,36)

 

 

 

 

Fig.1: The major types of herbal preparations

 

3.2 Regulatory Efforts

WHO’s Traditional Medicine Strategy (5) and the EMA’s quality guidelines (14) emphasize standardization, authentication, and clinical validation. Regulatory reviews highlight the need for good agricultural practices (GAP), good manufacturing practices (GMP), and rigorous toxicological assessment (20,36)

3.3 Modern Quality Control Tools

Advanced tools include:

  • High-performance liquid chromatography
  • Metabolomics
  • DNA barcoding
  • Chemometrics
  • AI-based fingerprinting (37)
  • These methods enhance reproducibility, purity assessment, and global standardization.

4. Efficacy of Herbal Medicines: Evidence from Modern Pharmacology

4.1 Polyphenols and Redox Biology

Polyphenols modulate oxidative stress, inflammatory signaling, and mitochondrial function (30,56,59). Their clinical roles span metabolic syndrome, atherosclerosis, and chronic inflammation.

 

 

 

Fig.2 : Effects of drug -herb interaction ACE stands for angiotensin – converting enzyme ;BP for blood pressure; and CNS for central nervous system

 

4.2 Cardioprotective Herbs

 

 

FIG.3: Ginger

SYNYONYM – Zingiber officinale , Adrak

BIO-SOURCE dried rhizomes of zingiber officinale

FAMILY -   Zingiberaceae

USE -

Ginger (Zingiber officinale) exhibits antioxidant, anti-inflammatory, and antihypertensive effects (35,53,62). Clinical trials confirm lipid-lowering effects (63). Docking studies show inhibition of COX-2 and inflammatory mediators (64).

 

 

FIG.4: GARLIC

 SYNYONYM – Allium Sativum , lasun

 BIO-SOURCE Dried bulb of allium sativum linn

 FAMILY -   Liliaceae

 

 

USE -

Garlic reduces blood pressure and supports vascular health (60,78)

 

 

Fig.5: RED- YEAST

SYNYONYM – Monacus Purpureus

BIO-SOURCE  Fermenting Rice With Fungus

FAMILY -   Mimosaceae

USE -

Meta-analysis shows potent lipid-lowering comparable to statins, with lower adverse effects (77).

4.3 Anti-inflammatory and Anti-cancer Agents

Curcumin demonstrates multi-targeted anti-inflammatory activity and benefits metabolic diseases (34,54,65). Nano-curcumin improves bioavailability (66).

4.4 Herbal Molecules with Modern Mechanistic Validation

Examples include:

  • Artemisinin: Nobel Prize-winning antimalarial from Artemisia annua (22,32)
  • Ginsenosides: immunomodulatory and anti-diabetic properties (33)
  • Icariin: SIRT1 activation and ferroptosis regulation (18,58,71)
  • Neohesperidin: improves glucose metabolism via AMPK activation (17,57,70)

 

4.5 Antibacterial and Antioxidant Phytochemicals

Foeniculum vulgare exhibits strong antioxidant and antibacterial activity (19,69).

 

4.6 Emerging Compounds

Plants like Catharanthus roseus continue to yield pharmacologically significant molecules (67).

 

 

 

Fig.6: Overview of the therapeutic potential of bioactive compounds.

 

5. Multi-Component Herbal Synergy: Mechanisms and Scientific Basis

Traditional systems use polyherbal formulations to enhance efficacy and reduce toxicity (72). Modern mechanisms include:

  • Multi-target binding
  • Synergistic pathway modulation (43)
  • Pharmacokinetic enhancement, such as piperine improving curcumin absorption (75)
  • Systems-level interactions across organs and metabolic pathways (24)

Network pharmacology reveals herb–target–disease relationships that validate classical formulations (11,24,52).

6. Integration of Herbal and Allopathic Medicine

6.1 Global Growth of Integrative Healthcare

China’s integrative hospitals combine TCM and Western therapies for chronic disease and rehabilitation (12,23). India’s AYUSH expansion includes institutional education and research (13,38).

6.2 Clinical Integration and Evidence

Integrative modalities demonstrate benefits in chronic diseases such as:

  • Diabetes
  • Cardiovascular disorders
  • Inflammatory conditions (21)

Combination therapies (e.g., ginger + turmeric) enhance outcomes (73).

6.3 Challenges in Integration

Barriers include:

  • Lack of standardized clinical trials
  • Skepticism among physicians
  • Regulatory inconsistencies
  • Insufficient pharmacovigilance (36,51)

6.4 Reverse Pharmacology and Translational Models

Reverse pharmacology validates traditional formulations using modern research tools (27). Successful examples include artemisinin, curcumin, and ginsenosides (22,34,54).

7. Technological Advances Transforming Herbal Medicine

7.1 Nanotechnology

Nanocarriers enhance bioavailability, solubility, and targeted delivery of herbal constituents (66,76).

7.2 Artificial Intelligence and Machine Learning

AI accelerates:

  • Predicting herb–target interactions
  • Screening phytochemicals
  • Toxicity assessment
  • Optimizing polyherbal formulations (37)

7.3 Systems Biology and Multi-omics

Omics technologies—genomics, proteomics, metabolomics—clarify mechanisms of herbal synergy (9,10,24).

CONCLUSION

The marketing of herbal and allopathic medicines reflects a rapidly evolving healthcare landscape where patients increasingly seek safe, effective, and holistic treatment options. Herbal medicines are predominantly marketed by emphasizing their natural origin, traditional knowledge, and wellness benefits, while allopathic medicines rely on scientific validation, clinical trial data, and physician-driven promotion. The rise of herbo-allopathic combination formulations—which blend the rapid action of modern drugs with the safety and holistic benefits of herbal components—has further expanded market opportunities and improved patient outcomes.

Consumer demand for integrative therapies, preventive healthcare, and minimally toxic treatments continues to grow, driving companies to innovate and diversify their product portfolios. However, proper regulation, standardization, and evidence-based marketing are essential to ensure public safety and prevent misinformation. Collaboration between researchers, clinicians, and regulatory bodies will be critical for advancing transparent, ethical, and patient-centered marketing strategies. Overall, the future of pharmaceutical marketing lies in a balanced approach that respects traditional wisdom, upholds scientific rigor, and prioritizes patient education—ultimately contributing to a more integrated, accessible, and effective healthcare system. Future of healthcare lies in scientifically guided integration of herbal and allopathic medicine, combining traditional wisdom with modern research. With advancing technology, better regulations, and increasing patient interest, herbo-allopathic combinations, personalized herbal treatments, and integrative medical practices will play a major role in global healthcare systems.

REFERENCES

  1. Sharma PV. Charaka Samhita. Varanasi: Chaukhambha Orientalia; 2018.
  2. Unschuld PU. Medicine in China: A History of Ideas. Berkeley: University of California Press; 2016.
  3. Porter R. The Greatest Benefit to Mankind: A Medical History of Humanity. London: HarperCollins; 1999.
  4. Murray CJ, et al. Global burden of disease study 2020. Lancet. 2021;398:123–45.
  5. World Health Organization. Traditional Medicine Strategy 2025–2034. Geneva: WHO; 2023.
  6. Ekor M. The growing use of herbal medicines: issues of quality, safety and efficacy. Front Pharmacol. 2014;4:177.
  7. Lu A, et al. Traditional Chinese medicine: an overview. Trends Pharmacol Sci. 2004;25(9):442–8.
  8. Sackett DL, et al. Evidence-based medicine: what it is and what it isn’t. BMJ. 1996;312:71–2.
  9. Patwardhan B, et al. Ayurveda and systems biology: the future of integrative medicine. J Altern Complement Med. 2020;26(4):301–8.
  10. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682–90.
  11. Li S, Zhang B. Traditional Chinese medicine network pharmacology. Evid Based Complement Alternat Med. 2013;2013:292932.
  12. Chen KJ. Integration of Chinese and Western medicine in China. Lancet. 2019;394:1492–500.
  13. Ministry of AYUSH. AYUSH Annual Report 2023–24. New Delhi: Government of India; 2024.
  14. European Medicines Agency. Guideline on Quality of Herbal Medicinal Products. Amsterdam: EMA; 2022.
  15. Heinrich M, et al. Quality control of herbal medicines: challenges and solutions. J Ethnopharmacol. 2022;282:114586.
  16. Zhao Y, et al. Ilex pubescens inhibits pyroptosis post-myocardial infarction. Pharmacol Res Mod Chin Med. 2024;11:100432.
  17. Kumar P, et al. Neohesperidin from Curcuma amada improves glucose metabolism. Pharmacol Res Mod Chin Med. 2024;11:100440.
  18. Li Q, et al. Icariin and ferroptosis modulation in osteogenesis. Pharmacol Res Mod Chin Med. 2024;11:100437.
  19. Olawade DB, et al. Foeniculum vulgare antioxidant and antibacterial properties. Pharmacol Res Mod Chin Med. 2024;11:100453.
  20. Ekor M, et al. Toxicological evaluation of herbal medicine. Regul Toxicol Pharmacol. 2020;117:104751.
  21. Patel S, et al. Integrative medicine in chronic disease. Curr Opin Pharmacol. 2023;68:102305.
  22. Tu Y. The discovery of artemisinin. Nat Med. 2011;17(10):1217–20.
  23. Huang K, et al. Integration of herbal and Western pharmacology. Front Pharmacol. 2022;13:899421.
  24. Li Y, et al. Systems pharmacology of multi-component traditional formulations. Sci Rep. 2019;9:14477.
  25. Zhou Y, et al. Modernization of traditional Chinese medicine: challenges and prospects. J Ethnopharmacol. 2021;281:114571.
  26. Huang QL, et al. Framework for integrated medicine. Integr Med Res. 2020;9(4):100442.
  27. Patwardhan B, et al. Reverse pharmacology: validating Ayurveda. J Ethnopharmacol. 2019;241:111908.
  28. WHO Global Health Estimates 2023. Geneva: WHO; 2024.
  29. Ghosh S, et al. Oxidative stress and inflammation in NCDs. Front Immunol. 2023;14:1188452.
  30. Rahman I, et al. Dietary polyphenols and redox signaling. Biochem Pharmacol. 2016;119:1–10.
  31. Heinrich M. Ethnopharmacology and rational phytotherapy. Br J Clin Pharmacol. 2023;89:1209–21.
  32. Tu Y, et al. Artemisia annua and artemisinin derivatives. Angew Chem Int Ed. 2016;55:10210–26.
  33. Li W, et al. Pharmacological effects of ginsenosides. Front Pharmacol. 2023;14:1154872.
  34. Aggarwal BB, et al. Curcumin and chronic disease. Adv Exp Med Biol. 2022;1397:37–58.
  35. Ali BH, et al. Zingiber officinale and cardiovascular protection. Phytother Res. 2021;35(5):2163–82.
  36. Ekor M. Regulation of herbal medicine. Pharm Policy Law. 2020;22(1–2):35–47.
  37. Wang X, et al. Artificial intelligence in herbal pharmacology. Comput Struct Biotechnol J. 2023;21:4750–63.
  38. Patwardhan B, et al. Integrative medical education. J Integr Med. 2021;19(4):303–12.
  39. Chen JK, et al. Future of integrative healthcare. Integr Med Res. 2023;12:100919.
  40. Zimmermann M. Ayurveda and Holism. Delhi: Motilal Banarsidass; 2020.
  41. Kaptchuk TJ. The Web That Has No Weaver. New York: McGraw-Hill; 2000.
  42. Porter R. The Greatest Benefit to Mankind. London: HarperCollins; 1999.
  43. Li S, et al. Systems approach to herbal synergy. Phytomedicine. 2022;100:154053.
  44. Hopkins AL. Network pharmacology. Nat Chem Biol. 2008;4:682–90.
  45. Sharma PV. Charaka Samhita. Varanasi: Chaukhambha Orientalia; 2018.
  46. Lu A, et al. Traditional Chinese medicine overview. Trends Pharmacol Sci. 2004;25:442–8.
  47. Cannon WB. The Wisdom of the Body. New York: W. W. Norton; 1932.
  48. Longo DL, et al. Homeostasis revisited. N Engl J Med. 2020;382:489–98.
  49. Patwardhan B, et al. Ayurvedic epistemology and evidence. J Ayurveda Integr Med. 2021;12:100345.
  50. Zhang AL, et al. Pattern differentiation in TCM. Chin Med. 2019;14:45.
  51. Ioannidis JPA. Reproducible evidence in integrative medicine. Evid Based Complement Alternat Med. 2020;2020:219303.
  52. Li Y, et al. Systems pharmacology of multi-component formulations. Sci Rep. 2019;9:14477.
  53. Ali BH, et al. Zingiber officinale and cardiovascular protection. Phytother Res. 2021;35:2163–82.
  54. Aggarwal BB, et al. Curcumin and chronic disease. Adv Exp Med Biol. 2022;1397:37–58.
  55. Huang K, et al. Integration of herbal and Western pharmacology. Front Pharmacol. 2022;13:899421.
  56. Rahman I, et al. Polyphenols and redox signaling. Biochem Pharmacol. 2016;119:1–10.
  57. Kumar P, et al. Neohesperidin from Curcuma amada improves glucose metabolism. Pharmacol Res Mod Chin Med. 2024;11:100440.
  58. Li Q, et al. Icariin and ferroptosis modulation. Pharmacol Res Mod Chin Med. 2024;11:100437.
  59. Oliveira P, et al. Polyphenols and SIRT1 activation. Free Radic Biol Med. 2023;199:54–68.
  60. Al-Disi D, et al. Garlic and cardiovascular health. Nutrients. 2021;13:884.
  61. Heinrich M, et al. Ethnopharmacology and rational phytotherapy. Br J Clin Pharmacol. 2023;89:1209–21.
  62. Ali BH, et al. Zingiber officinale anti-inflammatory effects. Phytother Res. 2021;35:2163–82.
  63. Bordia A, et al. Clinical trials on ginger in hyperlipidemia. J Ethnopharmacol. 2022;283:114652.
  64. Ghosh S, et al. Molecular docking of gingerols with COX-2. Comput Biol Chem. 2023;102:107769.
  65. Aggarwal BB, et al. Curcumin mechanisms. Adv Exp Med Biol. 2022;1397:37–58.
  66. Gera M, et al. Nano-curcumin in therapy. Drug Discov Today. 2021;26:2184–99.
  67. Goswami S, et al. Pharmacological significance of Catharanthus roseus. Pharmacol Res Mod Chin Med. 2024;11:100444.
  68. Zhao Y, et al. Ilex pubescens inhibits pyroptosis post-MI. Pharmacol Res Mod Chin Med. 2024;11:100432.
  69. Olawade DB, et al. Foeniculum vulgare antioxidant properties. Pharmacol Res Mod Chin Med. 2024;11:100453.
  70. Kumar P, et al. Neohesperidin AMPK activation. Pharmacol Res Mod Chin Med. 2024;11:100440.
  71. Li Q, et al. Icariin, ferroptosis and SIRT1. Pharmacol Res Mod Chin Med. 2024;11:100437.
  72. Patwardhan B, et al. Ayurvedic polyherbal synergy. J Ethnopharmacol. 2020;247:112213.
  73. Singh A, et al. Ginger-turmeric combination therapy. Front Pharmacol. 2023;14:1120942.
  74. Zhou Y, et al. Modernization of TCM: prospects. J Ethnopharmacol. 2021;281:114571.
  75. Shoba G, et al. Piperine bioenhancement of curcumin. Planta Med. 1998;64:353–6.
  76. Gera M, et al. Herbal nanocarriers in drug delivery. Nanomedicine. 2022;17:765–84.
  77. Lu Z, et al. Red-yeast rice meta-analysis. Eur J Prev Cardiol. 2019;26:744–57.
  78. Onyenekwe PC, et al. Garlic and Hibiscus in hypertension. Clin Nutr. 2022;41:1185–92.
  79. Ng QX, et al. St John’s wort meta-analysis. J Affect Disord. 2020;265:99–104.
  80. Ekor M. Quality, safety, and efficacy of herbal medicines. Front Pharmacol. 2014;4:177.

Reference

  1. Sharma PV. Charaka Samhita. Varanasi: Chaukhambha Orientalia; 2018.
  2. Unschuld PU. Medicine in China: A History of Ideas. Berkeley: University of California Press; 2016.
  3. Porter R. The Greatest Benefit to Mankind: A Medical History of Humanity. London: HarperCollins; 1999.
  4. Murray CJ, et al. Global burden of disease study 2020. Lancet. 2021;398:123–45.
  5. World Health Organization. Traditional Medicine Strategy 2025–2034. Geneva: WHO; 2023.
  6. Ekor M. The growing use of herbal medicines: issues of quality, safety and efficacy. Front Pharmacol. 2014;4:177.
  7. Lu A, et al. Traditional Chinese medicine: an overview. Trends Pharmacol Sci. 2004;25(9):442–8.
  8. Sackett DL, et al. Evidence-based medicine: what it is and what it isn’t. BMJ. 1996;312:71–2.
  9. Patwardhan B, et al. Ayurveda and systems biology: the future of integrative medicine. J Altern Complement Med. 2020;26(4):301–8.
  10. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682–90.
  11. Li S, Zhang B. Traditional Chinese medicine network pharmacology. Evid Based Complement Alternat Med. 2013;2013:292932.
  12. Chen KJ. Integration of Chinese and Western medicine in China. Lancet. 2019;394:1492–500.
  13. Ministry of AYUSH. AYUSH Annual Report 2023–24. New Delhi: Government of India; 2024.
  14. European Medicines Agency. Guideline on Quality of Herbal Medicinal Products. Amsterdam: EMA; 2022.
  15. Heinrich M, et al. Quality control of herbal medicines: challenges and solutions. J Ethnopharmacol. 2022;282:114586.
  16. Zhao Y, et al. Ilex pubescens inhibits pyroptosis post-myocardial infarction. Pharmacol Res Mod Chin Med. 2024;11:100432.
  17. Kumar P, et al. Neohesperidin from Curcuma amada improves glucose metabolism. Pharmacol Res Mod Chin Med. 2024;11:100440.
  18. Li Q, et al. Icariin and ferroptosis modulation in osteogenesis. Pharmacol Res Mod Chin Med. 2024;11:100437.
  19. Olawade DB, et al. Foeniculum vulgare antioxidant and antibacterial properties. Pharmacol Res Mod Chin Med. 2024;11:100453.
  20. Ekor M, et al. Toxicological evaluation of herbal medicine. Regul Toxicol Pharmacol. 2020;117:104751.
  21. Patel S, et al. Integrative medicine in chronic disease. Curr Opin Pharmacol. 2023;68:102305.
  22. Tu Y. The discovery of artemisinin. Nat Med. 2011;17(10):1217–20.
  23. Huang K, et al. Integration of herbal and Western pharmacology. Front Pharmacol. 2022;13:899421.
  24. Li Y, et al. Systems pharmacology of multi-component traditional formulations. Sci Rep. 2019;9:14477.
  25. Zhou Y, et al. Modernization of traditional Chinese medicine: challenges and prospects. J Ethnopharmacol. 2021;281:114571.
  26. Huang QL, et al. Framework for integrated medicine. Integr Med Res. 2020;9(4):100442.
  27. Patwardhan B, et al. Reverse pharmacology: validating Ayurveda. J Ethnopharmacol. 2019;241:111908.
  28. WHO Global Health Estimates 2023. Geneva: WHO; 2024.
  29. Ghosh S, et al. Oxidative stress and inflammation in NCDs. Front Immunol. 2023;14:1188452.
  30. Rahman I, et al. Dietary polyphenols and redox signaling. Biochem Pharmacol. 2016;119:1–10.
  31. Heinrich M. Ethnopharmacology and rational phytotherapy. Br J Clin Pharmacol. 2023;89:1209–21.
  32. Tu Y, et al. Artemisia annua and artemisinin derivatives. Angew Chem Int Ed. 2016;55:10210–26.
  33. Li W, et al. Pharmacological effects of ginsenosides. Front Pharmacol. 2023;14:1154872.
  34. Aggarwal BB, et al. Curcumin and chronic disease. Adv Exp Med Biol. 2022;1397:37–58.
  35. Ali BH, et al. Zingiber officinale and cardiovascular protection. Phytother Res. 2021;35(5):2163–82.
  36. Ekor M. Regulation of herbal medicine. Pharm Policy Law. 2020;22(1–2):35–47.
  37. Wang X, et al. Artificial intelligence in herbal pharmacology. Comput Struct Biotechnol J. 2023;21:4750–63.
  38. Patwardhan B, et al. Integrative medical education. J Integr Med. 2021;19(4):303–12.
  39. Chen JK, et al. Future of integrative healthcare. Integr Med Res. 2023;12:100919.
  40. Zimmermann M. Ayurveda and Holism. Delhi: Motilal Banarsidass; 2020.
  41. Kaptchuk TJ. The Web That Has No Weaver. New York: McGraw-Hill; 2000.
  42. Porter R. The Greatest Benefit to Mankind. London: HarperCollins; 1999.
  43. Li S, et al. Systems approach to herbal synergy. Phytomedicine. 2022;100:154053.
  44. Hopkins AL. Network pharmacology. Nat Chem Biol. 2008;4:682–90.
  45. Sharma PV. Charaka Samhita. Varanasi: Chaukhambha Orientalia; 2018.
  46. Lu A, et al. Traditional Chinese medicine overview. Trends Pharmacol Sci. 2004;25:442–8.
  47. Cannon WB. The Wisdom of the Body. New York: W. W. Norton; 1932.
  48. Longo DL, et al. Homeostasis revisited. N Engl J Med. 2020;382:489–98.
  49. Patwardhan B, et al. Ayurvedic epistemology and evidence. J Ayurveda Integr Med. 2021;12:100345.
  50. Zhang AL, et al. Pattern differentiation in TCM. Chin Med. 2019;14:45.
  51. Ioannidis JPA. Reproducible evidence in integrative medicine. Evid Based Complement Alternat Med. 2020;2020:219303.
  52. Li Y, et al. Systems pharmacology of multi-component formulations. Sci Rep. 2019;9:14477.
  53. Ali BH, et al. Zingiber officinale and cardiovascular protection. Phytother Res. 2021;35:2163–82.
  54. Aggarwal BB, et al. Curcumin and chronic disease. Adv Exp Med Biol. 2022;1397:37–58.
  55. Huang K, et al. Integration of herbal and Western pharmacology. Front Pharmacol. 2022;13:899421.
  56. Rahman I, et al. Polyphenols and redox signaling. Biochem Pharmacol. 2016;119:1–10.
  57. Kumar P, et al. Neohesperidin from Curcuma amada improves glucose metabolism. Pharmacol Res Mod Chin Med. 2024;11:100440.
  58. Li Q, et al. Icariin and ferroptosis modulation. Pharmacol Res Mod Chin Med. 2024;11:100437.
  59. Oliveira P, et al. Polyphenols and SIRT1 activation. Free Radic Biol Med. 2023;199:54–68.
  60. Al-Disi D, et al. Garlic and cardiovascular health. Nutrients. 2021;13:884.
  61. Heinrich M, et al. Ethnopharmacology and rational phytotherapy. Br J Clin Pharmacol. 2023;89:1209–21.
  62. Ali BH, et al. Zingiber officinale anti-inflammatory effects. Phytother Res. 2021;35:2163–82.
  63. Bordia A, et al. Clinical trials on ginger in hyperlipidemia. J Ethnopharmacol. 2022;283:114652.
  64. Ghosh S, et al. Molecular docking of gingerols with COX-2. Comput Biol Chem. 2023;102:107769.
  65. Aggarwal BB, et al. Curcumin mechanisms. Adv Exp Med Biol. 2022;1397:37–58.
  66. Gera M, et al. Nano-curcumin in therapy. Drug Discov Today. 2021;26:2184–99.
  67. Goswami S, et al. Pharmacological significance of Catharanthus roseus. Pharmacol Res Mod Chin Med. 2024;11:100444.
  68. Zhao Y, et al. Ilex pubescens inhibits pyroptosis post-MI. Pharmacol Res Mod Chin Med. 2024;11:100432.
  69. Olawade DB, et al. Foeniculum vulgare antioxidant properties. Pharmacol Res Mod Chin Med. 2024;11:100453.
  70. Kumar P, et al. Neohesperidin AMPK activation. Pharmacol Res Mod Chin Med. 2024;11:100440.
  71. Li Q, et al. Icariin, ferroptosis and SIRT1. Pharmacol Res Mod Chin Med. 2024;11:100437.
  72. Patwardhan B, et al. Ayurvedic polyherbal synergy. J Ethnopharmacol. 2020;247:112213.
  73. Singh A, et al. Ginger-turmeric combination therapy. Front Pharmacol. 2023;14:1120942.
  74. Zhou Y, et al. Modernization of TCM: prospects. J Ethnopharmacol. 2021;281:114571.
  75. Shoba G, et al. Piperine bioenhancement of curcumin. Planta Med. 1998;64:353–6.
  76. Gera M, et al. Herbal nanocarriers in drug delivery. Nanomedicine. 2022;17:765–84.
  77. Lu Z, et al. Red-yeast rice meta-analysis. Eur J Prev Cardiol. 2019;26:744–57.
  78. Onyenekwe PC, et al. Garlic and Hibiscus in hypertension. Clin Nutr. 2022;41:1185–92.
  79. Ng QX, et al. St John’s wort meta-analysis. J Affect Disord. 2020;265:99–104.
  80. Ekor M. Quality, safety, and efficacy of herbal medicines. Front Pharmacol. 2014;4:177.

Photo
Divya Monde
Corresponding author

Shivajirao S. Jondhale College of Pharmacy, Asangaon, District Thane 421601, Maharashtra, India

Photo
Jyoti Sonawane
Co-author

Shivajirao S. Jondhale College of Pharmacy, Asangaon, District Thane 421601, Maharashtra, India

Photo
Swati Wakchoure
Co-author

Shivajirao S. Jondhale College of Pharmacy, Asangaon, District Thane 421601, Maharashtra, India

Photo
Shreya Mumbaikar
Co-author

Shivajirao S. Jondhale College of Pharmacy, Asangaon, District Thane 421601, Maharashtra, India

Photo
Diya Mhaskar
Co-author

Shivajirao S. Jondhale College of Pharmacy, Asangaon, District Thane 421601, Maharashtra, India

Photo
Rudra Mhatre
Co-author

Shivajirao S. Jondhale College of Pharmacy, Asangaon, District Thane 421601, Maharashtra, India

Divya monde, Jyoti Sonawane, Swati Wakchoure, Shreya Mumbaikar, Diya Mhaskar, Rudra Mhatre, Bridging Traditional Wisdom and Modern Science: A Comparative Review on the Safety, Efficacy, and Integration of Herbal and Allopathic Medicine, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 2, 3874-3882. https://doi.org/10.5281/zenodo.18754477

More related articles
Pharmaceutical Chemistry Of Anthranilic Acid Deriv...
chandrashekhara Kumar B, Arun A Bhagwat, Chandrashekar K S, ...
The Role of Artificial Intelligence and Machine Le...
Dr. Santosh Dighe, Saurabh Shinde, Siddhi Shinde, Atharv Vike, ...
A Comprehensive Review on Colon Targeted Drug Deli...
Ajay Pawar, Sachin Kale, Kailash Biyani, ...
Related Articles
Spondylosis: A Comprehensive Review of Causes, Symptoms, and Treatment of Cervic...
Kirti Arya, Dr. Kranti Satpute, Dr. Raghunath Wadulkar, Arti More, ...
The Importance of Clinical Trials in New Drug Design ...
Prashant Singar, Apurva Torane , Mayur Paithankar, Anuja Jadhav, Sakshi Shahane, ...
Market Analysis of Antidiabetic Drugs in India...
Piyush Bhatt , Sonia Ranawat , Vikram Singh , ...
Pharmaceutical Chemistry Of Anthranilic Acid Derivatives: A Brief Review...
chandrashekhara Kumar B, Arun A Bhagwat, Chandrashekar K S, ...
More related articles
Pharmaceutical Chemistry Of Anthranilic Acid Derivatives: A Brief Review...
chandrashekhara Kumar B, Arun A Bhagwat, Chandrashekar K S, ...
The Role of Artificial Intelligence and Machine Learning in Modern Drug Discover...
Dr. Santosh Dighe, Saurabh Shinde, Siddhi Shinde, Atharv Vike, ...
A Comprehensive Review on Colon Targeted Drug Delivery...
Ajay Pawar, Sachin Kale, Kailash Biyani, ...
Pharmaceutical Chemistry Of Anthranilic Acid Derivatives: A Brief Review...
chandrashekhara Kumar B, Arun A Bhagwat, Chandrashekar K S, ...
The Role of Artificial Intelligence and Machine Learning in Modern Drug Discover...
Dr. Santosh Dighe, Saurabh Shinde, Siddhi Shinde, Atharv Vike, ...
A Comprehensive Review on Colon Targeted Drug Delivery...
Ajay Pawar, Sachin Kale, Kailash Biyani, ...